L2-Oxidation and Multimerization

Introduction
45
To date, at least thirteen different types of human papillomaviruses (HPVs) are defined as 46 'high-risk' (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) or 'probably high-risk' (HPV 68) 47 for they have been linked to cancer development (3). These HPV types are consistently respectively (13, 32) . They are 'virus-like particle' (VLP) vaccines based on the L1 major 58 capsid protein. Up to date, more than 100 million doses have been administered and both 59 vaccines show an impressive safety and efficacy profile (17, 27) . It is expected that the two 60 vaccines will reduce the rate of cervical cancer in vaccinated women by 70-80%. 61 Despite their clinical success, VLP vaccines have some important limitations, the major one 62 being their rather narrow range of protection. The principle underlying VLP vaccines is the 63 induction of neutralizing antibodies that block virus infection by binding to surface, L1 64 protein loops that are highly heterogeneous among different HPV types (6-8, 10). 
L2-Oxidation and Multimerization
Materials & Methods
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Construction of TrxL2 multimers
98
The 3 construct was generated as previously described (28 1:500 in PBS. After washing three times with PBS-0.3%Tween20, the plates were blocked for 160 1h at 37°C with 0.2% casein dissolved in PBS (50 µl/well). Next, monoclonal K18L2 20-38 (0.5 161 mg/ml) was serially diluted 1:2 on the plate (50 µl/well ) starting from a 1:100 dilution.
162
Incubation was allowed to proceed at 37°C for 1 hour before washing with PBS-0.3% 163 Tween20. A secondary, goat-anti-mouse HRP-conjugated antibody (10 mg/ml, Dianova,
164
Germany) was then added to the plate (50 µl/well) at a 1:3000 dilution and incubated for 1h 165 at 37°C. After washing with PBS-0.3%Tween20 (100 µl/well), 1 mg/ml ABTS substrate (2,2′- 
